Haematologica (Sep 2007)

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

  • Massimo Breccia,
  • Giuseppe Cimino,
  • Daniela Diverio,
  • Fabiana Gentilini,
  • Franco Mandelli,
  • Francesco Lo Coco

DOI
https://doi.org/10.3324/haematol.11329
Journal volume & issue
Vol. 92, no. 9

Abstract

Read online

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.